Valuation: Fresenius

Market Cap 26.03B 30.4B 24.29B 22.29B 41.88B 2,909B 42.7B 288B 112B 1,458B 114B 112B 4,826B P/E 2026 *
14.2x
P/E 2027 * 12.3x
Enterprise Value 36.4B 42.51B 33.96B 31.16B 58.55B 4,068B 59.71B 403B 157B 2,039B 160B 156B 6,749B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.43x
Free-Float
73%
Yield 2026 *
2.51%
Yield 2027 * 2.69%
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2022
Director of Finance/CFO 46 31/08/2022
Compliance Officer 50 -
Director TitleAgeSince
Director/Board Member 71 19/05/2015
Director/Board Member 65 12/05/2016
Director/Board Member 52 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 30.63B
+0.46%-1.00%+32.79%+40.19% 120B
-0.41%-1.30%-0.92%+47.88% 88.13B
+0.14%+2.67%+31.42%+82.36% 26.68B
-0.25%+2.41%-5.63%-8.54% 22.22B
+2.02%+2.80%+50.88%+283.24% 21.62B
-0.27%-2.92%-10.20%+11.84% 14.18B
-0.10%-0.24%-5.59%-7.22% 12.65B
-0.42%-1.60%+28.29%+73.03% 11.3B
+0.23%-0.92%-18.89%+87.22% 10.15B
Average +0.03%+0.22%+11.35%+67.78% 36.3B
Weighted average by Cap. +0.14%-0.51%+17.05%+58.01%

Financials

2026 *2027 *
Net sales 23.76B 27.75B 22.17B 20.34B 38.22B 2,655B 38.98B 263B 103B 1,331B 104B 102B 4,406B 24.98B 29.17B 23.31B 21.38B 40.18B 2,791B 40.97B 276B 108B 1,399B 110B 107B 4,631B
Net income 1.89B 2.2B 1.76B 1.62B 3.04B 211B 3.1B 20.9B 8.15B 106B 8.28B 8.1B 350B 2.16B 2.52B 2.01B 1.85B 3.47B 241B 3.54B 23.86B 9.3B 121B 9.45B 9.25B 400B
Net Debt 10.37B 12.11B 9.67B 8.88B 16.68B 1,159B 17.01B 115B 44.74B 581B 45.47B 44.48B 1,923B 9.57B 11.18B 8.93B 8.2B 15.4B 1,070B 15.7B 106B 41.3B 536B 41.98B 41.07B 1,775B
Logo Fresenius
Fresenius SE & Co. KGaA is a Germany-based healthcare group focused on products and services for the treatment of critically and chronically ill patients. The Company operates through its core businesses, Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and supplies biopharmaceuticals, clinical nutrition products, medical technologies, intravenously administered generic drugs, and infusion therapies. Fresenius Helios is Europe’s private healthcare provider, operating hospitals, outpatient centers, and other healthcare facilities in Germany, Spain, and Latin America. Fresenius also holds an investment in Fresenius Medical Care, a provider of dialysis products and services for patients with chronic kidney disease.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
46.64EUR
Average target price
55.86EUR
Spread / Average Target
+19.76%

Quarterly revenue - Rate of surprise